%A Peng,Li %A Zhang,Zhen %A Zhao,Dachun %A Zhao,Jialin %A Mao,Feng %A Sun,Qiang %D 2021 %J Pathology and Oncology Research %C %F %G English %K Biomolecular status,Discordance,Recurrence,metastatic disease,PFS 3,breast cancer,Surrogate subtypes %Q %R 10.3389/pore.2021.599894 %W %L %M %P %7 %8 2021-April-09 %9 Original Research %+ Dr Qiang Sun,Peking Union Medical College Hospital (CAMS),Beijing,100730,Beijing Municipality,China,sunqiang2019@sina.com %# %! Immunohistochemical changes following progression in early-stage BC %* %< %T Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases %U https://www.por-journal.com/articles/10.3389/pore.2021.599894 %V 27 %0 JOURNAL ARTICLE %@ 1532-2807 %X Background: The objective was to explore the discordance in the expression of the estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67 between primary and recurrent/metastatic lesions in patients with early stage breast cancer as well as the prognostic impact.Method: Patients with early-stage primary breast cancer and confirmed recurrence/metastasis at Peking Union Medical College Hospital between January 2005 and August 2018 were screened. The details of discordance in each parameter between primary and recurrent/metastatic lesions and progression were recorded. Regression and survival analysis were applied to determine the association and clinical impact of the discordance.Results: We evaluated 75 patients. The discordance rate of ER, PR, HER2, and Ki-67 expression was 9.3, 14.7, 14.7, and 21.5%, respectively. Additionally, 66.7, 11.8, 14.3, and 0% of patients with Luminal A, Luminal B, HER2, and triple-negative primary tumors presented with a different subtype for the recurrent/metastatic tumors, respectively. No statistical difference in progression-free survival was observed according to the subtype of the recurrent or metastatic breast cancer (p > 0.05). Among 69 patients for whom treatment was adjusted after recurrence or metastasis, 66 patients remained recurrence-free during the follow-up period.Conclusion: For patients with early-stage breast cancer, the ER, PR, HER2, and Ki-67 expression profile for recurrent/metastatic tumors does not always match that of the primary tumor. After adjusting treatment according to the receptor expression in recurrent/metastatic lesions, most patients remained progression-free during the follow-up period.